Posted on 553
Aviceda Therapeutics, a late-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing the composition of the Executive Team that will guide the company through ongoing development of breakthrough, first-in-class therapeutics and continued growth opportunities as a business entity.
Serving in key leadership roles on Aviceda’s Executive Leadership Team will be:
Mohamed Genead, MD, CEO & President,
David Callanan, MD, Chief Medical Officer,
Derek Kunimoto, MD, JD, Chief Operating Officer,
Michael Tolentino, MD, Chief Technology Officer, and
Christopher Scott, PhD, Chief Scientific Officer.